Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia

Infection

Volumn 42, Issue 3, 2014, Pages 553-558

  Lakatos, B ^a   Jakopp, B ^a   Widmer, A ^a   Frei, R ^a   Pargger, H ^a   Elzi, L ^a   Battegay, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antimicrobial therapy; Bacteraemia; Bacteraemia mortality; Stenotrophomonas maltophilia; Trimethoprim sulfamethoxazole

Indexed keywords

CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITAL INFECTION; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA BACTEREMIA; TERTIARY CARE CENTER; URBAN AREA; VENTILATOR ASSOCIATED PNEUMONIA; VERY ELDERLY; ADOLESCENT; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL; ISOLATION AND PURIFICATION; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, URBAN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84901687379     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0607-3     Document Type: Article

References (11)

1. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia : an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312-23.
2. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26:229-37. (Pubitemid 46572029)
3. Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Curr Drug Saf. 2013;8:114-9.
4. Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38:211-5.
5. Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81:114-8.
6. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22:508-12. (Pubitemid 26259182)
7. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653-6. (Pubitemid 34615454)
8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32. (Pubitemid 351763841)
9. Carroll KC, Cohen S, Nelson R, Campbell DM, Claridge JD, Garrison MW, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998;32:229-35. (Pubitemid 29017744)
10. Fihman V, Le Monnier A, Corvec S, Jaureguy F, Tankovic J, Jacquier H, et al. Stenotrophomonas maltophilia - the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64:391-8.
11. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis. 2001;32:S104-13. (Pubitemid 32424265)